Roche's checkpoint player Tecentriq flops in another bladder cancer subset
Just weeks after Merck’s star checkpoint inhibitor Keytruda secured FDA approval for a subset of bladder cancer patients, Swiss competitor Roche’s Tecentriq has failed in a pivotal bladder cancer study.
The 809-patient trial — IMvigor010 — tested the PD-L1 drug in patients with muscle-invasive urothelial cancer (MIUC) who had undergone surgery, and were at high risk for recurrence.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,500+ biopharma pros reading Endpoints daily — and it's free.